Gilead Sciences (NASDAQ:GILD) reported Q2 non-GAAP diluted earnings of $1.34, down from $1.58 a year earlier.
Analysts surveyed by Capital IQ expected $1.64.
Revenue for the quarter ended June 30 was $6.60 billion, up from $6.26 billion a year earlier.
Analysts surveyed by Capital IQ expected $6.45 billion.
The company said it expects full-year 2023 non-GAAP diluted EPS of $6.45 to $6.80, down from the previous outlook of $6.60 to $7. Analysts surveyed by Capital IQ expect $6.73.
The company expects product sales for the year of $26.3 billion to $26.7 billion, compared with previous outlook of $26.0 billion to $26.5 billion.
Gilead said its board maintained a quarterly dividend of $0.75 per share, payable on Sept. 28 to stockholders of record on Sept. 15.